Serum inducible protein-10 chemokine as a biomarker for clearance of HCV with and without treatment in Egyptian patients-Reference-Cited by-同舟云学术

Serum inducible protein-10 chemokine as a biomarker for clearance of HCV with and without treatment in Egyptian patients

Published:2019-11-15 Issue:4 Volume:27 Page:265-273
ISSN:1875-869X
Container-title:Human Antibodies
language:
Short-container-title:HAB

Author:

Tabll Ashraf¹,El Shenawy Reem¹,Elsharkawy Hazem²,Mohamed Faten Zahran²

Affiliation:

1. Microbial Biotechnology Department, National Research Centre, Giza, Egypt

2. Chemistry Department, Faculty of Science, Zakazik University, Cairo, Egypt

Publisher

IOS Press

Subject

General Medicine,Immunology,Immunology and Allergy

Reference31 articles.

1. Evaluation of the role of alpha-fetoprotein (afp) levels in chronic viral hepatitis c patients;Abd-elfatah;Without Hepatocellular Carcinoma (HCC),2014

2. Real life Egyptian experience of efficacy and safety of Simeprevir/Sofosbuvir therapy in 6211 chronic HCV genotype IV infected patients;Abdo;Liver Int,2016

3. Naturalizing activity and safety of human monoclonal antibodies against of hepatitis C virus;Abelhafez;Hum. Antibodies,2017

4. J. Ahmad, K.R. Reddy, H.L. Tillmann, P.H. Hayashi, N. Chalasani, R.J. Fontana, V.J. Navarro, A. Stolz, H. Barnhart, G.A. Cloherty and J.H. Hoofnagle, Importance of hepatitis c virus RNA testing in patients with suspected drug-induced liver injury, Dig. Dis. Sci (2019).

5. Epidemiology, disease burden, and treatment strategies of chronic hepatitis C virus infections in Saudi Arabia in the new treatment paradigm shift;Aljumah;Saudi J. Gastroenterol,2016

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The impact of cytokine change after hepatitis C virus clearance by direct antiviral agents on the risk of hepatocellular carcinoma;Journal of the Formosan Medical Association;2021-03

2. CXCL9 chemokine level is associated with spontaneous clearance and sustained virological response in Egyptian Chronic Hepatitis C patients receiving direct acting antivirals;Human Antibodies;2020-07-09